*Refresh the page if the below document does not appear.
ANDA approval granted to Granules India for Loperamide Hydrochloride & Simethicone Tablets
US FDA has authorized Granules India Limited’s Abbreviated New Drug Application (ANDA) for Loperamide Hydrochloride and Simethicone Tablets, 2 mg/125 mg.
Anuva, based in India & UK, teams up with US genomics major
A global strategic partnership has been reached with Helix, one of the top population genomics and viral surveillance companies in the US, by a genomics biotech company with a centre in India and backing from a hub in the UK.
Ryaltris launched in US by Glenmark's partner Hikma
FDA has approved RYALTRIS for the treatment of seasonal allergic rhinitis (SAR) symptoms in adult and paediatric patients 12 years of age and older, according to Glenmark Specialty S.A., a Glenmark subsidiary.
Zydus Lifesciences initiated Phase IV clinical trials for novel drug 'Desidustat'
Zydus Lifesciences, a major pharmaceutical company, announced that it will start phase-IV clinical trials for the drug Desidustat, which is used to treat patients with anaemia caused by chronic kidney disease (CKD).
Novo Holdings invests $50 million in MedGenome to accelerate its expansion into new markets
Novo Holdings, a global leader in life science investing, announced a $50 million investment in MedGenome, the premier provider of genetic diagnostics, research, and data in South Asia.
Cardiovascular cell therapy delivery agreement signed by Bayer's BlueRock
With the help of BioCardia, Bayer’s BlueRock Therapeutics has partnered to deliver cell therapies, paying a “significant” upfront fee to gain access to minimally invasive technology that might help deliver its heart failure candidate drugs to their intended patients.
Bayer started phase III study to investigate oral FXIa inhibitor asundexian
Asundexian, an oral Factor XIa (FXIa) inhibitor,
is being studied as a potential new treatment for
atrial fibrillation, non-cardioembolic ischemic
stroke, and high-risk transient ischemic attack
patients in a phase III clinical development
programme called “OCEANIC” by Bayer.
